Formulation and specifications: Injection: 100 mg (4 ml)/vial
Indications: Bevacizumab in combination with platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-squamous cell NSCLC.
Key points for rational drug use:
1. Bevacizumab is not indicated for the treatment of advanced squamous cell carcinoma of the lung.
2. Patients who have severe bleeding or have had recent hemoptysis or tumor invasion of large blood vessels should not receive bevacizumab therapy.
3. Bevacizumab in combination with platinum-based chemotherapy should be given for a maximum of 6 cycles, followed by maintenance therapy with bevacizumab alone or in combination with a chemotherapeutic agent available for maintenance therapy, such as pemetrexed, until disease progression or intolerable toxicity occurs.
4. The recommended dose of bevacizumab is 15 mg/kg, administered every 3 weeks. Alternatively, 7.5 mg/kg administered every 3 weeks may be used.
5. Discontinue bevacizumab in the presence of (1) severe gastrointestinal adverse reactions (gastrointestinal perforation, gastrointestinal fistula formation, abdominal abscess), visceral fistula formation. (2) Wound dehiscence requiring interventional treatment and complications of wound healing. (3) Severe bleeding (e.g. requiring interventional treatment) (4) Severe arterial thrombotic events. (5) Life-threatening (grade 4) venous thromboembolic events, including pulmonary embolism. (6) Hypertensive crisis or hypertensive encephalopathy. (7) Reversible posterior encephalopathy syndrome. (8) Nephrotic syndrome.
6. Bevacizumab needs to be suspended if the following conditions occur: (1) 4 to 6 weeks before elective surgery, at least 28 days after surgery and until full wound recovery. (2) Severe hypertension that is poorly controlled by medication. (3) Moderate to severe proteinuria requiring further evaluation. (4) Severe infusion reaction.
*7. In the European Union, bevacizumab in combination with erlotinib is approved for the first-line treatment of patients with non-surgically resectable advanced, metastatic or recurrent non-squamous NSCLC with sensitive mutations in the EGFR gene. This indication has not yet been approved in China and may be used with adequate communication with the patient.